Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 May;98(5):1217-1224.
doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

Cornelius F Waller  1 , Gopinath M Ranganna  2 , Eduardo J Pennella  3 , Christopher Blakeley  4 , Miguel H Bronchud  5 , Leonard A Mattano Jr  6 , Oleksandr Berzoy  7 , Nataliia Voitko  8 , Yaroslav Shparyk  9 , Iryna Lytvyn  10 , Andriy Rusyn  11 , Vasil Popov  12 , István Láng  13 , Katrin Beckmann  14 , Rajiv Sharma  15 , Mark Baczkowski  16 , Mudgal Kothekar  17 , Abhijit Barve  3
Affiliations
Clinical Trial

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

Cornelius F Waller et al. Ann Hematol. 2019 May.

Abstract

Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as prophylaxis for chemotherapy-induced neutropenia. This was a phase 3, multicenter, randomized, double-blind, parallel-group equivalence trial of MYL-1401H vs European Union-sourced reference pegfilgrastim. Patients with newly diagnosed stage II/III breast cancer eligible to receive (neo) adjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide every 3 weeks for 6 cycles were enrolled and randomized 2:1 to 6 mg of MYL-1401H or reference pegfilgrastim 24 h (+ 2-h window after the first 24 h) after the end of chemotherapy. The primary efficacy endpoint was the duration of severe neutropenia in cycle 1 (i.e., days with absolute neutrophil count (ANC) < 0.5 × 109/L). Mean (standard deviation (SD)) duration of severe neutropenia in MYL-1401H and reference pegfilgrastim groups was 1.2 days (0.93) and 1.2 days (1.10), respectively. The 95% CI for least squares mean difference (- 0.285, 0.298) was within the predefined equivalence range of ± 1 day. Secondary endpoints, including grade ≥ 3 neutropenia (frequency, 91% and 82% for MYL-1401H and reference pegfilgrastim, respectively), time to ANC nadir (mean (SD), 6.2 (0.98) and 6.3 (1.57) days), and duration of post-nadir recovery (mean (SD), 1.9 (0.85) and 1.7 (0.91) days) were comparable. Overall safety profiles of the study drugs were comparable. MYL-1401H demonstrated equivalent efficacy and similar safety to reference pegfilgrastim and may be an equivalent option for reducing incidence of neutropenia. ( ClinicalTrials.gov , NCT02467868; EudraCT, 2014-002324-27).

Keywords: Biosimilar; Chemotherapy-induced neutropenia; Febrile neutropenia; Pegfilgrastim.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

CF Waller and MH Bronchud are consultants/advisory board members for Mylan. GM Ranganna, EJ Pennella, K Beckmann, M Baczkowski, and A Barve are paid employees of Mylan and may hold stock with the company. C Blakeley is a paid employee of Worldwide Clinical Trials. LA Mattano Jr. has served as a consultant for Alexion, Mylan, Novartis, and Pfizer and may hold stock with Pfizer. R Sharma was a paid employee of Mylan at the time of analysis and may hold stock with the company. M Kothekar is a paid employee of Biocon Research Ltd. and may hold stock with the company. All remaining authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Statement of informed consent

Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Mean ANC over time by treatment in cycle 1 (PP population). ANC absolute neutrophil count, PP per protocol
See this image and copyright information in PMC

References

    1. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6:469–478. - PMC - PubMed
    1. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411–419. doi: 10.1093/annonc/mdm345. - DOI - PubMed
    1. Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Glob Oncol. 2017;2016:008607. - PMC - PubMed
    1. US Food and Drug Administration (2015) Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformat.... Accessed 16 August 2018
    1. European Medicines Agency (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin.... Accessed 16 August 2018

Publication types

MeSH terms

Associated data